119 related articles for article (PubMed ID: 32924331)
1. Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction.
Straw S; McGinlay M; Relton SD; Koshy AO; Gierula J; Paton MF; Drozd M; Lowry JE; Cole C; Cubbon RM; Witte KK; Kearney MT
ESC Heart Fail; 2020 Dec; 7(6):3859-3870. PubMed ID: 32924331
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
[TBL] [Abstract][Full Text] [Related]
4. The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction.
Benes J; Kotrc M; Jarolim P; Hoskova L; Hegarova M; Dorazilova Z; Podzimkova M; Binova J; Lukasova M; Malek I; Franekova J; Jabor A; Kautzner J; Melenovsky V
ESC Heart Fail; 2021 Apr; 8(2):1417-1426. PubMed ID: 33512782
[TBL] [Abstract][Full Text] [Related]
5. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
[TBL] [Abstract][Full Text] [Related]
6. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
[TBL] [Abstract][Full Text] [Related]
7. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.
Manolis AS; Manolis AA; Manolis TA; Melita H
Heart Fail Rev; 2019 Nov; 24(6):847-866. PubMed ID: 31147814
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV
Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020
[TBL] [Abstract][Full Text] [Related]
10. Effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure and concurrent coronary atherosclerosis.
Byrne C; Ahlehoff O; Elming MB; Pedersen F; Pehrson S; Nielsen JC; Eiskjaer H; Videbaek L; Svendsen JH; Haarbo J; Thøgersen AM; Køber L; Thune JJ
ESC Heart Fail; 2022 Apr; 9(2):1287-1293. PubMed ID: 35106935
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.
El Moheb M; Nicolas J; Khamis AM; Iskandarani G; Akl EA; Refaat M
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012738. PubMed ID: 30537022
[TBL] [Abstract][Full Text] [Related]
12. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH
Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
Mezu U; Adelstein E; Jain S; Saba S
Am J Cardiol; 2011 Sep; 108(5):718-22. PubMed ID: 21640321
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
[TBL] [Abstract][Full Text] [Related]
15. Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction.
Fernández-Vázquez D; Ferrero-Gregori A; Álvarez-García J; Gómez-Otero I; Vázquez R; Delgado Jiménez J; Worner Diz F; Bardají A; García-Pavía P; Bayés-Genís A; González-Juanatey JR; Cinca J; Pascual Figal DA
Rev Esp Cardiol (Engl Ed); 2020 Jul; 73(7):561-568. PubMed ID: 31974070
[TBL] [Abstract][Full Text] [Related]
16. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
[TBL] [Abstract][Full Text] [Related]
18. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model.
Shadman R; Poole JE; Dardas TF; Mozaffarian D; Cleland JG; Swedberg K; Maggioni AP; Anand IS; Carson PE; Miller AB; Levy WC
Heart Rhythm; 2015 Oct; 12(10):2069-77. PubMed ID: 26142301
[TBL] [Abstract][Full Text] [Related]
19. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.
Rørth R; Thune JJ; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Bruun NE; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Kristensen SL
Europace; 2019 Aug; 21(8):1203-1210. PubMed ID: 31323662
[TBL] [Abstract][Full Text] [Related]
20. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
